Kala Bio Inc (KALA)
6.59
-0.14
(-2.08%)
USD |
NASDAQ |
May 17, 16:00
6.59
0.00 (0.00%)
After-Hours: 20:00
Kala Bio Net Income (Quarterly): -8.627M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -8.627M |
| September 30, 2023 | -8.704M |
| June 30, 2023 | -10.41M |
| March 31, 2023 | -14.46M |
| December 31, 2022 | -12.84M |
| September 30, 2022 | 29.07M |
| June 30, 2022 | -28.11M |
| March 31, 2022 | -32.94M |
| December 31, 2021 | -47.57M |
| September 30, 2021 | -28.13M |
| June 30, 2021 | -36.50M |
| March 31, 2021 | -30.41M |
| December 31, 2020 | -31.11M |
| September 30, 2020 | -27.95M |
| June 30, 2020 | -23.31M |
| March 31, 2020 | -21.96M |
| Date | Value |
|---|---|
| December 31, 2019 | -21.96M |
| September 30, 2019 | -23.18M |
| June 30, 2019 | -23.82M |
| March 31, 2019 | -25.39M |
| December 31, 2018 | -25.22M |
| September 30, 2018 | -15.60M |
| June 30, 2018 | -14.62M |
| March 31, 2018 | -11.30M |
| December 31, 2017 | -11.29M |
| September 30, 2017 | -10.18M |
| June 30, 2017 | -10.99M |
| March 31, 2017 | -9.759M |
| December 31, 2016 | -8.395M |
| September 30, 2016 | -9.667M |
| June 30, 2016 | -9.853M |
| March 31, 2016 | -5.252M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-47.57M
Minimum
Dec 2021
29.07M
Maximum
Sep 2022
-21.21M
Average
-23.31M
Median
Jun 2020
Net Income (Quarterly) Benchmarks
| CEL-SCI Corp | -7.245M |
| AIM ImmunoTech Inc | -12.58M |
| IGC Pharma Inc | -5.589M |
| NovaBay Pharmaceuticals Inc | -3.214M |
| Protalix BioTherapeutics Inc | -4.595M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 7.486M |
| EPS Diluted (Quarterly) | -3.18 |
| Enterprise Value | 1.743M |
| Earnings Yield | -273.9% |
| Normalized Earnings Yield | -996.49 |